Catalyst
Slingshot members are tracking this event:
Portola Pharmaceuticals Announces Full Results of Phase 3 APEX Study of Betrixaban Presented at International Society on Thrombosis and Haemostasis (ISTH) Meeting
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| PTLA | Community voting in process | |||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 27, 2016
Related Projects
- Diving into Portola's strategy laid out in the NEJM for obtaining FDA approval of Betrixaban in preventing VTE in Acute Medically Ill patients after APEX failed. PTLA Executed On: Feb 14, 2017 at 12:00 PM EST
Related Keywords
Phase 3 Apex Study, Betrixaban, Haemostasis, Thrombosis
